In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued
Bayer has restructured and expanded its ongoing partnership with Recursion Pharmaceuticals on artificial intelligence-powered drug discovery, switching to a focus on cance
Roche has formed a decade-long alliance with Recursion Pharma that will focus on using machine learning and "industrialised" drug discovery to find new neuroscience and cancer drugs.
